Pharmacological Targeting of the Hepcidin/Ferroportin Axis
作者： Nicole Wilkinson , Kostas Pantopoulos , Giada Sebastiani
关键词:
摘要: The iron regulatory hormone hepcidin limits fluxes to the bloodstream by promoting degradation of exporter ferroportin in target cells. Hepcidin insufficiency causes hyperabsorption dietary iron, hyperferremia and tissue overload, which are hallmarks hereditary hemochromatosis. Similar responses also observed iron-loading anemias due ineffective erythropoiesis (such as thalassemias, dyserythropoietic myelodysplastic syndromes) chronic liver diseases. On other hand, excessive expression inhibits absorption leads hypoferremia retention within macrophages. This reduces availability for erythroblasts contributes development with iron-restricted anemia disease iron-refractory iron-deficiency anemia). Pharmacological targeting hepcidin/ferroportin axis may offer considerable therapeutic benefits correcting traffic. review summarizes principles underlying hepcidin-based therapies treatment iron-related disorders, discusses emerging strategies manipulating pathways.
frontiersin.org
core.ac.uk
scilit.net 参考文章(96)
Paul J. Schmidt, Mark D. Fleming, Modulation of Hepcidin as Therapy for Primary and Secondary Iron Overload Disorders: Preclinical Models and Approaches Hematology-oncology Clinics of North America. ,vol. 28, pp. 387- 401 ,(2014) , 10.1016/J.HOC.2013.11.004
Derrick R Witcher, Donmienne Leung, Karen A Hill, David C De Rosa, Jianghuai Xu, Joseph Manetta, Victor J Wroblewski, Robert J Benschop, LY2928057, An Antibody Targeting Ferroportin, Is a Potent Inhibitor Of Hepcidin Activity and Increases Iron Mobilization In Normal Cynomolgus Monkeys Blood. ,vol. 122, pp. 3433- 3433 ,(2013) , 10.1182/BLOOD.V122.21.3433.3433
Ken Tsuchiya, Kosaku Nitta, Hepcidin is a potential regulator of iron status in chronic kidney disease. Therapeutic Apheresis and Dialysis. ,vol. 17, pp. 1- 8 ,(2013) , 10.1111/1744-9987.12001
Tomas Ganz, Elizabeta Nemeth, Iron homeostasis in host defence and inflammation Nature Reviews Immunology. ,vol. 15, pp. 500- 510 ,(2015) , 10.1038/NRI3863
Karin E Finberg, Rebecca Whittlesey, Mark D Fleming, Nancy C Andrews, Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice. Blood. ,vol. 117, pp. 4590- 4599 ,(2009) , 10.1182/BLOOD-2010-10-315507
Aurélie Gudjoncik, Charles Guenancia, Marianne Zeller, Yves Cottin, Catherine Vergely, Luc Rochette, The iron-regulatory hormone hepcidin: a possible therapeutic target? Pharmacology & Therapeutics. ,vol. 146, pp. 35- 52 ,(2015) , 10.1016/J.PHARMTHERA.2014.09.004
Maura Poli, Michela Asperti, Annamaria Naggi, Natascia Campostrini, Domenico Girelli, Michela Corbella, Marina Benzi, Celine Besson-Fournier, Helene Coppin, Federica Maccarinelli, Dario Finazzi, Paolo Arosio, Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Blood. ,vol. 123, pp. 1564- 1573 ,(2014) , 10.1182/BLOOD-2013-07-515221
Airie Kim, Elizabeta Nemeth, New insights into iron regulation and erythropoiesis. Current Opinion in Hematology. ,vol. 22, pp. 199- 205 ,(2015) , 10.1097/MOH.0000000000000132
Paul J. Schmidt, Iva Toudjarska, Anoop K. Sendamarai, Tim Racie, Stuart Milstein, Brian R. Bettencourt, Julia Hettinger, David Bumcrot, Mark D. Fleming, An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe -/- mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia Blood. ,vol. 121, pp. 1200- 1208 ,(2013) , 10.1182/BLOOD-2012-09-453977
Frank Schwoebel, Lucas T. van Eijk, Dirk Zboralski, Simone Sell, Klaus Buchner, Christian Maasch, Werner G. Purschke, Martin Humphrey, Stefan Zöllner, Dirk Eulberg, Frank Morich, Peter Pickkers, Sven Klussmann, The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys Blood. ,vol. 121, pp. 2311- 2315 ,(2013) , 10.1182/BLOOD-2012-09-456756